Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.75 |
| ▸ | THRB | P10828 | 7/20 | 0.75 |
| ▸ | BLM | P54132 | 7/20 | 0.75 |
| ▸ | RECQL | P46063 | 6/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.75 |
| ▸ | TOP2A | P11388 | 5/20 | 0.75 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.75 |
| ▸ | STAT6 | P42226 | 3/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147968 | 0.97 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL43830 | 0.94 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL27900762 | 0.94 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL1771543 | 0.94 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL248564 | 0.92 | S100A4 (0.85) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL28160744 | 0.92 | S100A4 (0.84) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL331063 | 0.92 | S100A4 (0.84) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL22409662 | 0.91 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL27834123 | 0.91 | MEN1 (0.91) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL29048581 | 0.91 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120040346-A1 | Method of Determining Chemotherapy of Metastatic Tumor by Assaying DPD Gene Expression in Primary Tumors | DANENBERG KATHLEEN D (US) | 2012-02-16 | — | — | US | disclosed |
| US-8105568-B2 | Vitamin receptor binding drug delivery conjugates | ENDOCYTE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8101402-B2 | Medical device for analyte monitoring and drug delivery | THERANOS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1662987-B1 | MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY | THERANOS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110243951-A1 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS | UNIVERSITY OF MIAMI (US) | 2011-10-06 | — | — | US | disclosed |
| US-8026062-B2 | Using thymidylate synthase concentration as evaluative tool in determining dosage levels to treating cell proliferative disorders | RESPONSE GENETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110230736-A1 | DEVICE AND METHOD FOR DRUG EVALUATION AND LOCAL TREATMENT | NINEPOINT MEDICAL, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110166553-A1 | MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY | LABRADOR DIAGNOSTICS LLC | 2011-07-07 | — | — | US | disclosed |
| EP-2320991-A2 | DEVICE AND METHOD FOR DRUG EVALUATION AND LOCAL TREATMENT | Third Rock Ventures (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2319403-A2 | Analyte monitoring and drug delivery | Theranos, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | MEN1 3425/4885KMT2A 2852/4885THRB 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.